

The effect of treatment on the microbiota of patients diagnosed with colonic lesions

Marc A Sze¹, Nielson T Baxter², Mack T Ruffin IV³, Mary AM Rogers², and Patrick D Schloss^{1†}

† To whom correspondence should be addressed: pschloss@umich.edu

1 Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

2 Department of Internal Medicine, University of Michigan, Ann Arbor, MI

3 Department of Family Medicine and Community Medicine, Penn State Hershey Medical Center, Hershey, PA

Abstract

Background. Colorectal cancer (CRC) is a worldwide health problem. Despite growing evidence that members of the gut microbiota can drive tumorigenesis, little is known about what happens to the microbiota after treatment for an adenoma or carcinoma. This study tested the hypothesis that treatment for adenoma or carcinoma alters the abundance of bacterial populations associated with disease to those associated with a normal colon. We tested this hypothesis by sequencing the 16S rRNA genes in the feces of 67 individuals before and after treatment for adenoma (N=22), advanced adenoma (N=19), and carcinoma (N=26).

Results. There were large changes to the bacterial communities associated with treatment across the three groups. The communities from patients with carcinomas changed significantly more than those with adenoma following treatment (P-value < 0.001). There was no significant change in the microbiota between patients with adenoma and advanced adenoma, or between patients with advanced adenoma and carcinoma (P-value > 0.05). Although treatment was associated with intrapersonal changes, the change in the abundance of individual OTUs to treatment was not consistent within diagnosis groups (P-value > 0.05). Because the distribution of OTUs across patients and diagnosis groups was irregular, we used the Random Forest machine learning algorithm to identify groups of OTUs that allowed us to successfully distinguish between pre and post-treatment samples for each of the diagnosis groups. Although the three models successfully differentiated between the pre and post-treatment samples, there was little overlap between the OTUs that were indicative of treatment. Next, we used a larger cohort that contained individuals with normal colons and those with adenomas, advanced adenomas, and carcinomas to determine whether individuals who underwent treatment were more likely to have OTUs associated with normal colons. We again built Random Forest models and measured the change in the positive probability of having one of the

three diagnoses. Only patients who had carcinomas experienced a significant decrease in positive probability of having a lesion after treatment ($P\text{-value} < 0.05$), indicating that the microbial milieu of the colon more closely resembled that of a normal colon. Finally, we tested whether the type of treatment impacted the microbiota of those diagnosed with carcinomas and were unable to detect any significant differences in characteristics of these communities between individuals treated with surgery alone and those treated with chemotherapy or chemotherapy and radiation ($P\text{-value} > 0.05$).

Conclusions. Further exploration of the relationship between diagnosis, treatment, and the impact on the microbiota will yield improvements in disease management.

Keywords

microbiota; colorectal cancer; polyps; treatment; risk factor.

Background

Colorectal cancer (CRC) is the third most common cause of cancer deaths in the United States [1,2]. Disease mortality has significantly decreased, predominately due to improvements in screening [2]. Despite these improvements, there are still approximately 50,000 CRC-related deaths per year in the United States [1]. Current estimates indicate that 20-30% of those who undergo treatment will experience recurrence and 35% of all patients will die within five years [3–5]. Identification of methods to assess patients' risk of recurrence is of great importance to reduce mortality and healthcare costs.

There is growing evidence that the gut microbiota is involved in the progression of CRC. Mouse-based studies have identified populations of *Bacteroides fragilis*, *Escherichia coli*, and *Fusobacterium nucleatum* that alter disease progression [6–10]. Furthermore, studies that shift the structure of the microbiota through the use of antibiotics or inoculation of germ free mice with human feces have shown that varying community compositions can result in varied tumor burden [11–13]. Collectively, these studies support the hypothesis that the microbiota can alter the amount of inflammation in the colon and with it the rate of tumorigenesis [14].

Building upon this evidence, several human studies have identified unique signatures of colonic lesions [15–20]. One line of research has identified community-level differences between those bacteria that are found on and adjacent to colonic lesions and have supported a role for *Bacteroides fragilis*, *Escherichia coli*, and *Fusobacterium nucleatum* in tumorigenesis [21–23]. Others have proposed feces-based biomarkers that could be used to diagnose the presence of colonic adenomas and carcinomas [24–26]. These studies have associated *Fusobacterium nucleatum* and other oral pathogens with colonic lesions (adenoma, advanced adenoma, and carcinoma). They have also noted that the loss of bacteria generally thought to produce short chain fatty acids, which can suppress

inflammation, is associated with colonic lesions. This suggests that gut bacteria have a role in tumorigenesis with potential as useful biomarkers for aiding in the early detection of disease.

Despite advances in understanding the role between the gut microbiota and colonic tumorigenesis, we still do not understand how treatments including resection, chemotherapy, and/or radiation affect the composition of the gut microbiota. If the community drives tumorigenesis then one would hypothesize that treatment to remove a lesion would affect the microbiota and risk of recurrence. To test this hypothesis, we addressed two related questions: Does treatment affect the colonic microbiota in a predictable manner? If so, does the treatment alter the community to more closely resemble that of individuals with normal colons?

We answered these questions by sequencing the V4 region of 16S rRNA genes amplified from fecal samples of individuals with adenoma, advanced adenoma, and carcinomas pre and post-treatment. We used classical community analysis to compare the alpha and beta-diversity of communities pre and post treatment. Next, we generated Random Forest models to identify bacterial populations that were indicative of treatment for each diagnosis group. Finally, we measured the predictive probabilities to assess whether treatment yielded bacterial communities similar to those individuals with normal colons. We found that treatment alters the composition of the gut microbiota and that, for those with carcinomas, the gut microbiota shifted more towards that of a normal colon after treatment. In the individuals with carcinomas, no difference was found by the type of treatment (surgery alone versus surgery with chemotherapy). Understanding how the community responds to these treatments could be a valuable tool for identifying biomarkers to quantify the risk of recurrence and the likelihood of survival.

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

7

8

[illegible]

10

[illegible]

[illegible]

[illegible]

distribution of OTUs across individuals limited the statistical power of the test. To overcome these problems we developed Random Forest models to identify collections of OTUs that would allow us to differentiate between pre and post-treatment samples from each of the diagnosis groups. Because of the relatively small number of subjects in each group, we restricted our models to only incorporate 10 OTUs to limit the likelihood that the models would overfit the data. Despite this restriction, the models performed well (adenoma AUC range = 0.69 - 0.92, advanced adenoma AUC range = 0.80 - 1.00, carcinoma AUC range = 0.82 - 0.98). Interestingly, the 10 OTUs that were used for each model had little overlap with each other [Figure 2]. These results support the earlier community-wide analysis where we observed that the treatment had an impact on the overall community structure; however, the effect of treatment was not consistent across patients and diagnosis groups.

Post-treatment samples from patients with carcinoma more closely resemble those of a normal colon.

Next, we determined whether treatment changed the microbiota in a way that the post-treatment communities resembled that of patients with normal colons. To test this, we used an expanded cohort of 423 individuals that were diagnosed under the same protocol as having normal colons or colons with adenoma, advanced adenoma, or carcinoma [Table 2]. We then constructed Random Forest models to classify the study samples, with the 3 diagnosis groups (adenoma, advanced adenoma, or carcinoma), or having a normal colon. The models performed well (adenoma AUC range = 0.62 - 0.72, advanced adenoma AUC range = 0.68 - 0.77, carcinoma AUC range = 0.84 - 0.90; Figure S1). The OTUs that were incorporated into the adenoma and advanced adenoma models largely overlapped and those OTUs that were used to classify the carcinoma samples were largely distinct from those of the other two models [Figure 3A]. Among the OTUs that were shared across the three models were those populations generally considered beneficial to their host (e.g. *Faecalibacterium*, *Lachnospiraceae*, *Bacteroides*, *Dorea*, *Anaerostipes*, and *Roseburia*) [Figures 3B]. Although many of these OTUs were also included in the model differentiating between patients with normal colons and those with carcinoma, this model

also included OTUs affiliated with populations that have previously been associated with carcinoma (*Fusobacterium*, *Porphyromonas*, *Parvimonas*) [24–26] [Figure S2] with some individuals showing a marked decrease in relative abundance [Figure S3]. Finally, we applied these three models to the pre and post-treatment samples for each diagnosis group and quantified the change in the positive probability of the model. A decrease in the positive probability would indicate that the microbiota more closely resembled that of a patient with a normal colon. There was no significant change in the positive probability for the adenoma or advanced adenoma groups [Figure 4]. The positive probability for the pre and post-treatment samples from patients diagnosed with carcinoma significantly decreased with treatment, suggesting a shift toward a normal microbiota for most individuals. Only, 6 of the 26 patients (23.08%) who were diagnosed with a carcinoma had a higher positive probability after treatment; one of those was re-diagnosed with carcinoma on the follow up visit. These results indicate that, although there were changes in the microbiota associated with treatment, those experienced by patients with carcinoma after treatment yielded gut bacterial communities of greater similarity to that of a normal colon.

Difficult to identify effects of specific treatments on the change in the microbiota.

The type of treatment that the patients received varied across diagnosis groups. Those with adenomas and advanced adenomas received surgical resection (adenoma, N=4; advanced adenoma, N=4) or polyp removal during colonoscopy (adenoma, N=18; advanced adenoma, N=15) and those with carcinomas received surgical resection (N=12), surgical resection with chemotherapy (N=9), and surgical resection with chemotherapy and radiation (N=5). We focused on the patients with carcinoma and pooled those patients that received chemotherapy with those that received chemotherapy and radiation to improve our statistical power. We did not observe a significant difference in the effect of these treatments on the number of observed OTUs, Shannon diversity, or Shannon evenness (P-value > 0.05). Furthermore, there was not a significant difference in the effect of the treatments on the amount of change in the community structure (P-value = 0.298).

383 Finally, the change in the positive probability was not significantly different between the
384 two treatment groups (P-value = 0.999). Due to the relatively small number of samples in
385 each treatment group, it was difficult to make a definitive statement regarding the specific
386 type of treatment on the amount of change in the structure of the microbiota.

Discussion

This study builds upon previous work that demonstrated a role for the microbiota in tumorigenesis and that microbiome-derived biomarkers can detect colonic lesions [6–10,24–28]. Our study focused on comparing the microbiota of patients diagnosed with adenoma, advanced adenoma, and carcinoma before and after treatment. For all three groups of patients, we observed changes in their microbiota. After treatment, the microbiota of patients with carcinoma changed significantly more than the other groups. This change resulted in communities that more closely resembled those of patients with a normal colon. This may suggest that treatment for carcinoma is not only successful for removing the carcinoma but also at reducing the associated bacterial communities. Understanding the effect of treatment on the microbiota of those diagnosed with carcinomas may have important implications for reducing disease recurrence. It is intriguing that it may be possible to use microbiome-based biomarkers to not only predict the presence of lesions but to assess the risk of recurrence.

Patients diagnosed with adenoma and advanced adenoma, however, did not experience a shift towards a community structure that resembled those with normal colons. This may be due to the fundamental differences between the features of adenomas and advanced adenomas and carcinoma. Specifically, carcinomas may create an inflammatory milieu that would impact the structure of the community and removal of that stimulus would alter said structure. In addition, it is possible that the difference between the microbiota of patients with adenoma and advanced adenoma and those with normal colons is subtle. This is supported by the reduced ability of our models to correctly classify patients with adenomas and advanced adenomas relative to those diagnosed with carcinomas [Figure S1]. Given the irregular distribution of microbiota across patients in the different diagnosis groups, it is possible that we lacked the statistical power to adequately characterize the change in the communities following treatment.

There was a subset of patients (6 of the 26 with carcinomas) who demonstrated an elevated probability of carcinoma after treatment. This may reflect an elevated risk of recurrence. The 23.08% prevalence of increased carcinoma probability from our study is within the expected rate of recurrence (20-30% [3,4]). We hypothesized that these individuals may have had more severe tumors; however, the tumor severity of these 6 individuals (3 with Stage II and 3 with Stage III) was similar to the distribution observed among the other 20 patients. We also hypothesized that we may have sampled these patients later than the rest and their communities may have reverted to a carcinoma-associated state; however, there was not a statistically significant difference in the length of time between sample collection among those whose probabilities increased or decreased (Wilcoxon Test; P-value = 0.56). Finally, it is possible that these patients may not have responded to treatment as well as the other 20 patients diagnosed with carcinoma and so the microbiota may not have been impacted the same way. Again, further studies looking at the role of the microbiota in recurrence are needed to understand the dynamics following treatment.

Our final hypothesis was that the specific type of treatment altered the structure of the microbiome. The treatment to remove adenomas and advanced adenomas was either polyp removal or surgical resection whereas it was surgical resection alone or in combination with chemotherapy or with chemotherapy and radiation for individuals with carcinoma. Because chemotherapy and radiation target rapidly growing cells, these treatments would be more likely to cause a turnover of the colonic epithelium driving a more significant change in the structure of the microbiota. Although, we were able to test for an effect across these specific types of treatment, the number of patients in each treatment group was relatively small.

This study expands upon existing research that has established a role for the microbiota in tumorigenesis and that demonstrated the utility of microbiome-based biomarkers to predict the presence of colonic lesions. The most exciting future direction from the current study is

439 the possibility that markers within the microbiota could be used to evaluate the effect of
440 treatment and predict recurrence for those diagnosed with carcinoma. If such an approach
441 is effective, it might be possible to target the microbiota as part of adjuvant therapy. Our
442 data provides additional evidence on the importance of the microbiota in tumorigenesis by
443 addressing the recovery of the microbiota after treatment and opens interesting avenues
444 of research into how these changes may affect recurrence.

Methods

Study Design and Patient Sampling. Sampling and design have been previously reported in Baxter, et al [24]. Briefly, study exclusion involved those who had already undergone surgery, radiation, or chemotherapy, had colorectal cancer before a baseline fecal sample could be obtained, had IBD, a known hereditary non-polyposis colorectal cancer, or familial adenomatous polyposis. Samples used to build the models for prediction were collected either prior to a colonoscopy or between one and two weeks after initial colonoscopy. The bacterial community has been shown to normalize back to a pre-colonoscopy community within this time period [29]. Our study cohort consisted of 67 individuals with an initial sample as described and a follow up sample obtained between 188 - 546 days after treatment of lesion [Table 1]. Patients were diagnosed by colonoscopic examination and histopathological review of any biopsies taken. Patients were classified as having advanced adenoma if they had an adenoma greater than 1 cm, more than three adenomas of any size, or an adenoma with villous histology. This study was approved by the University of Michigan Institutional Review Board. All study participants provided informed consent and the study itself conformed to the guidelines set out by the Helsinki Declaration.

16S rRNA Gene Sequencing. Sequencing was completed as described by Kozich, et al. [30]. DNA extraction used the 96-well Soil DNA isolation kit (MO BIO Laboratories) and an epMotion 5075 automated pipetting system (Eppendorf). The V4 variable region was amplified and the resulting product was split between four sequencing runs with normal, adenoma, and carcinoma evenly represented on each run. Each group was randomly assigned to avoid biases based on sample collection location. The pre and post-treatment samples were sequenced on the same run.

Sequence Processing. The mothur software package (v1.37.5) was used to process

the 16S rRNA gene sequences and has been previously described [30]. The general workflow using mothur included merging paired-end reads into contigs, filtering for low quality contigs, aligning to the SILVA database [31], screening for chimeras using UCHIME [32], classifying with a naive Bayesian classifier using the Ribosomal Database Project (RDP)[33], and clustered into Operational Taxonomic Units (OTUs) using a 97% similarity cutoff with an average neighbor clustering algorithm [34]. The number of sequences for each sample was rarefied to 10523 to minimize the impacts of uneven sampling.

Model Building. The Random Forest [35] algorithm was used to create the three models used. The adenoma model classified normal versus adenoma, the advanced adenoma model classified normal versus advanced adenoma, and the carcinoma model classified normal versus carcinoma. The total number of individuals in the treatment models was 67 individuals. There were a total of 22 individuals in the treatment adenoma model, 19 individuals in the treatment advanced adenoma model, and 26 individuals in the treatment carcinoma model [Table 1]. The total number of individuals in the normal versus diagnosis models was 423 individuals [Table 2]. There were a total of 239 individuals in the adenoma model, 262 individuals in the advanced adenoma model, and 266 individuals in the carcinoma model [Table 2]. Each model was then applied to our 67-person cohort [Table 1] which assessed the prediction of pre-treatment adenoma (adenoma n = 22 and disease free n = 0) versus post-treatment adenoma (adenoma n = 0 and disease free n = 22), pre-treatment advanced adenoma (advanced adenoma n = 19 and disease free n = 0) versus post-treatment advanced adenoma (advanced adenoma n = 0 and disease free n = 19), pre-treatment carcinoma (carinoma n = 26 and disease free n = 0) versus post-treatment carcinoma (carcinoma n = 1 and disease free n = 25).

The model included only OTU data obtained from 16S rRNA sequencing. Non-binary data was checked for near zero variance and OTUs that had near zero variance were removed. This pre-processing was performed with the R package caret (v6.0.73). Optimization of

the mtry hyper-parameter involved making 100 different 80/20 (train/test) splits of the data where normal and adenoma, normal and advanced adenoma, or normal and carcinoma were represented in the same proportion within both the whole data set and the 80/20 split. For each of the different splits, 20 repeated 10-fold cross validation was performed on the 80% component to optimize the mtry hyper-parameter by maximizing the AUC (Area Under the Curve of the Receiver Operator Characteristic). The resulting model was then tested on the hold out data obtained from the 20% component. All three models had an optimized mtry of 2. The hyper-parameter, mtry, defines the number of variables to investigate at each split before a new division of the data was created with the Random Forest model.

Assessment of the most important OTUs to the model involved counting the number of times an OTU was present in the top 10% of mean decrease in accuracy (MDA) for each of the 100 different splits run. This was then followed with filtering of this list to variables that were only present in more than 50% of these 100 runs. The final collated list of variables was then run through the mtry optimization again. Once the ideal mtry was found the entire sample set specific to normal versus adenoma, normal versus advanced adenoma, or normal versus carcinoma was used to create the final Random Forest model on which classifications on the 67-person cohort was completed. For all three models the final optimized mtry was 2. The only difference other than the sample set used between treatment models and normal versus diagnosis models was that only the top 10 OTUs were used to build each respective treatment model by diagnosis group to help avoid model overfitting.

Statistical Analysis. The R software package (v3.3.2) was used for all statistical analysis. Comparisons between bacterial community structure utilized PERMANOVA [36] in the vegan package (v2.4.1). Comparisons between probabilities as well as overall OTU differences between pre and post-treatment samples utilized a paired Wilcoxon ranked sum test. Where multiple comparison testing was appropriate, a Benjamini-Hochberg (BH)

correction was applied [37] and a corrected P-value of less than 0.05 was considered significant. Unless otherwise stated the P-values reported are those that were BH corrected. Model rank importance was determined by obtaining the median MDA from the 100, 20 repeated 10-fold cross validation and then ranking from largest to smallest MDA.

Reproducible Methods. A detailed and reproducible description of how the data were processed and analyzed can be found at https://github.com/SchlossLab/Size_followUps_2017. Raw sequences have been deposited into the NCBI Sequence Read Archive (SRP062005 and SRP096978) and the necessary metadata can be found at <https://www.ncbi.nlm.nih.gov/Traces/study/> and searching the respective SRA study accession.

Figure 1: General Differences between Adenoma, Advanced Adenoma, and Carcinoma Groups After Treatment. A) Thetayc distance from pre versus post sample within each individual. A significant difference was found between the adenoma and carcinoma group for thetacyc (P-value = 5.36e-05). Solid black points represent the median value for each diagnosis group. B) NMDS of the pre and post-treatment samples for the adenoma group. C) NMDS of the pre and post-treatment samples for the advanced adenoma group. D) NMDS of the pre and post-treatment samples for the carcinoma group.

Figure 2: The 10 OTUs used to classify treatment for Adenoma, Advanced Adenoma, and Carcinoma. A) Adenoma OTUs. B) Advanced Adenoma OTUs. C) Carcinoma OTUs.

Figure 3: Common OTUs to All Models. A) Venn diagram showing the OTU overlap between each model. B) For each common OTU the lowest taxonomic identification and importance rank for each model run is shown.

Figure 4: Treatment Response Based on Models Built for Adenoma, Advanced Adenoma, or Carcinoma. A) Positive probability change from initial to follow up sample in those with adenoma. B) Positive probability change from initial to follow up sample in those with advanced adenoma. C) Positive probability change from initial to follow up sample in those with carcinoma.

Table 1: Demographic Data of pre and Post Treatment Cohort

	Adenoma	Advanced Adenoma	Carcinoma
n	22	19	26
Age (Mean \pm SD)	61.68 \pm 7.2	63.11 \pm 10.9	61.65 \pm 12.9
Sex (%F)	36.36	36.84	42.31
BMI (Mean \pm SD)	26.86 \pm 3.9	25.80 \pm 4.7	28.63 \pm 7.2
Caucasian (%)	95.45	84.21	96.15

Table 2: Demographic Data of Training Cohort

	Normal	Adenoma	Advanced Adenoma	Carcinoma
n	172	67	90	94
Age (Mean \pm SD)	54.29 \pm 9.9	63.01 \pm 13.1	64.07 \pm 11.3	64.37 \pm 12.9
Sex (%F)	64.53	46.27	37.78	43.62
BMI (Mean \pm SD)	26.96 \pm 5.3	25.68 \pm 4.8	26.66 \pm 4.9	29.27 \pm 6.7
Caucasian (%)	87.79	92.54	92.22	94.68

Figure S1: ROC Curves of the Adenoma, Advanced Adenoma, and Carcinoma

Models. A) Adenoma ROC curve: The light green shaded areas represent the range of values of a 100 different 80/20 splits of the test set data and the dark green line represents the model using 100% of the data set and what was used for subsequent classification. B) Advanced Adenoma ROC curve: The light yellow shaded areas represent the range of values of a 100 different 80/20 splits of the test set data and the dark yellow line represents the model using 100% of the data set and what was used for subsequent classification. C) Carcinoma ROC curve: The light red shaded areas represent the range of values of a 100 different 80/20 splits of the test set data and the dark red line represents the model using 100% of the data set and what was used for subsequent classification.

Figure S2: Summary of Important OTUs for the Adenoma, Advanced Adenoma, and

Carcinoma Models. A) MDA of the most important variables in the adenoma model. The dark green point represents the mean and the lighter green points are the value of each of the 100 different runs. B) Summary of Important Variables in the advanced adenoma model. MDA of the most important variables in the SRN model. The dark yellow point represents the mean and the lighter yellow points are the value of each of the 100 different runs. C) MDA of the most important variables in the carcinoma model. The dark red point represents the mean and the lighter red points are the value of each of the 100 different runs.

Figure S3: Pre and Post Treatment Relative Abundance of CRC associated OTUs within the Carcinoma Model.

Declarations

Ethics approval and consent to participate

The University of Michigan Institutional Review Board approved this study, and all subjects provided informed consent. This study conformed to the guidelines of the Helsinki Declaration.

Consent for publication

Not applicable.

Availability of data and material

A detailed and reproducible description of how the data were processed and analyzed can be found at https://github.com/SchlossLab/Size_followUps_2017. Raw sequences have been deposited into the NCBI Sequence Read Archive (SRP062005 and SRP096978) and the necessary metadata can be found at <https://www.ncbi.nlm.nih.gov/Traces/study/> and searching the respective SRA study accession.

Competing Interests

All authors declare that they do not have any relevant competing interests to report.

Funding

This study was supported by funding from the National Institutes of Health to P. Schloss (R01GM099514, P30DK034933) and to the Early Detection Research Network (U01CA86400).

Authors' contributions

All authors were involved in the conception and design of the study. MAS analyzed the data. NTB processed samples and analyzed the data. All authors interpreted the data. MAS and PDS wrote the manuscript. All authors reviewed and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors thank the Great Lakes-New England Early Detection Research Network for providing the fecal samples that were used in this study. We would also like to thank Amanda Elmore for reviewing and correcting code error and providing feedback on manuscript drafts. We would also like to thank Nicholas Lesniak for providing feedback on manuscript drafts.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA: a cancer journal for clinicians*. 2016;66:7–30.
2. Haggard FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery*. 2009;22:191–7.
3. Hellinger MD, Santiago CA. Reoperation for recurrent colorectal cancer. *Clinics in Colon and Rectal Surgery*. 2006;19:228–36.
4. Ryuk JP, Choi G-S, Park JS, Kim HJ, Park SY, Yoon GS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. *Annals of Surgical Treatment and Research*. 2014;86:143–51.
5. Institute NC. SEER Cancer Stat Facts: Colon and Rectum Cancer [Internet]. [cited 2017 Apr 27]. Available from: <http://seer.cancer.gov/statfacts/html/colorect.html>
6. Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, et al. Polyamine catabolism contributes to enterotoxigenic *Bacteroides fragilis*-induced colon tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108:15354–9.
7. Abed J, Emgård JEM, Zamir G, Faroja M, Almogy G, Grenov A, et al. Fap2 Mediates *Fusobacterium nucleatum* Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. *Cell Host & Microbe*. 2016;20:215–25.
8. Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced

colorectal cancer. *Nature Communications*. 2014;5:4724.

9. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host & Microbe*. 2013;14:207–15.

10. Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nature Medicine*. 2009;15:1016–22.

11. Zackular JP, Baxter NT, Chen GY, Schloss PD. Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis. *mSphere*. 2016;1.

12. Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, et al. The gut microbiome modulates colon tumorigenesis. *mBio*. 2013;4:e00692–00613.

13. Baxter NT, Zackular JP, Chen GY, Schloss PD. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. *Microbiome*. 2014;2:20.

14. Flynn KJ, Baxter NT, Schloss PD. Metabolic and Community Synergy of Oral Bacteria in Colorectal Cancer. *mSphere*. 2016;1.

15. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *The ISME journal*. 2012;6:320–9.

16. Chen H-M, Yu Y-N, Wang J-L, Lin Y-W, Kong X, Yang C-Q, et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. *The American Journal of Clinical Nutrition*. 2013;97:1044–52.

17. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated

- 645 microbiota in patients with colorectal cancer. PloS One. 2012;7:e39743.
- 646 18. Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, et al. Molecular
647 characterization of mucosal adherent bacteria and associations with colorectal adenomas.
648 Gut Microbes. 2010;1:138–47.
- 649 19. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic
650 analysis identifies association of Fusobacterium with colorectal carcinoma. Genome
651 Research. 2012;22:292–8.
- 652 20. Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome
653 development along the colorectal adenoma-carcinoma sequence. Nature Communications.
654 2015;6:6528.
- 655 21. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al.
656 Microbiota organization is a distinct feature of proximal colorectal cancers. Proceedings of
657 the National Academy of Sciences of the United States of America. 2014;111:18321–6.
- 658 22. Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al.
659 Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA oncology.
660 2015;1:653–61.
- 661 23. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, et al.
662 Intestinal inflammation targets cancer-inducing activity of the microbiota. Science (New
663 York, N.Y.). 2012;338:120–3.
- 664 24. Baxter NT, Ruffin MT, Rogers MAM, Schloss PD. Microbiota-based model improves the
665 sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Medicine.
666 2016;8:37.
- 667 25. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential of

668 fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology*.
669 2014;10:766.

670 26. Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as
671 a screening tool for colorectal cancer. *Cancer Prevention Research (Philadelphia, Pa.)*.
672 2014;7:1112–21.

673 27. Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of
674 faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer.
675 *Gut*. 2017;66:70–8.

676 28. Warren RL, Freeman DJ, Pleasance S, Watson P, Moore RA, Cochrane K, et al.
677 Co-occurrence of anaerobic bacteria in colorectal carcinomas. *Microbiome*. 2013;1:16.

678 29. O'Brien CL, Allison GE, Grimpen F, Pavli P. Impact of colonoscopy bowel preparation
679 on intestinal microbiota. *PloS One*. 2013;8:e62815.

680 30. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a
681 dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence
682 data on the MiSeq Illumina sequencing platform. *Applied and Environmental Microbiology*.
683 2013;79:5112–20.

684 31. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, et al. SILVA: A
685 comprehensive online resource for quality checked and aligned ribosomal RNA sequence
686 data compatible with ARB. *Nucleic Acids Research*. 2007;35:7188–96.

687 32. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity
688 and speed of chimera detection. *Bioinformatics (Oxford, England)*. 2011;27:2194–200.

689 33. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid
690 assignment of rRNA sequences into the new bacterial taxonomy. *Applied and*

Environmental Microbiology. 2007;73:5261–7.

34. Schloss PD, Westcott SL. Assessing and improving methods used in operational taxonomic unit-based approaches for 16S rRNA gene sequence analysis. *Applied and Environmental Microbiology*. 2011;77:3219–26.

35. Breiman L. Random Forests. *Machine Learning* [Internet]. 2001 [cited 2013 Feb 7];45:5–32. Available from: <http://link.springer.com/article/10.1023/A%3A1010933404324>
<http://link.springer.com/article/10.1023%2FA%3A1010933404324?LI=true>

36. Anderson MJ, Walsh DCI. PERMANOVA, ANOSIM, and the Mantel test in the face of heterogeneous dispersions: What null hypothesis are you testing? *Ecological Monographs* [Internet]. 2013 [cited 2017 Jan 5];83:557–74. Available from: <http://doi.wiley.com/10.1890/12-2010.1>

37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)*. 1995;57:289–300.